Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung clinical trials
7 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
This study is testing if adding two new drugs, nivolumab and ipilimumab, to standard chemotherapy works better than chemotherapy alone for advanced lung cancer. It seeks to understand if this new combination helps people live longer.
For: Stage IV Non-Small Cell Lung Cancer (NSCLC)Spain · Ireland · Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
This study is looking at new ways to treat bladder cancer that has spread or can't be removed with surgery. It compares a new combination of medicines with standard chemotherapy to see which works best at helping people live longer. Participants will be randomly assigned to different treatment groups.
For: Untreated Unresectable or Metastatic Urothelial CancerGermany · Greece · Denmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS- 986205, Followed by Continued Post- Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer
This study is looking at new ways to treat bladder cancer that has grown into the muscle. It compares standard chemotherapy with chemotherapy plus new immunotherapy drugs (like Nivolumab) before and after surgery, to see which approach works best and is safest.
For: Bladder Cancer Muscle-Invasive Bladder CancerGermany · Norway · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non–Small Cell Lung Cancer (POD1UM-304)
This study looks at a new drug, retifanlimab, alongside standard chemotherapy for advanced lung cancer. It aims to see if adding retifanlimab helps people live longer and if it's safe. It's for adults with specific types of non-small cell lung cancer that has spread.
For: Metastatic nonsquamous or squamous non-small cell lung cancerCzechia · Bulgaria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Nonsmall Cell Lung Cancer (LA NSCLC)
This study is looking at new ways to treat a type of lung cancer that hasn't spread widely. It compares standard treatments with new drug combinations to see if they can stop the cancer from growing for longer. It aims to find the best treatment for patients with this type of lung cancer.
For: Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)France · Netherlands · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
This study looks at new ways to treat early-stage lung cancer. It compares standard chemotherapy with treatments that combine chemotherapy with new medicines called nivolumab and ipilimumab, to see if they work better at stopping the cancer from returning.
For: Early Stage Non-Small Cell Lung Cancer (NSCLC)France · Italy · Romania - AuthorisedTherapeutic exploratory (Phase II)
Durvalumab (MEDI4736) in combination with consolidative radiochemotherapy and ablative stereotactic radiotherapy in extensive stage SCLC
This study is looking at a new way to treat an advanced type of lung cancer called extensive stage small cell lung cancer. It combines standard treatments like chemotherapy and radiotherapy with a new drug called Durvalumab (Imfinzi) to see if it can stop the cancer from growing for longer.
For: extensive stage small cell lung cancer (SCLC)Germany